ALK-Abelló A/S (AKBLF)
USD 21.35
(-4.47%)
USD 21.35
(-4.47%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.27 Billion DKK | -1.77% |
| 2022 | 2.32 Billion DKK | -1.28% |
| 2021 | 2.35 Billion DKK | -2.49% |
| 2020 | 2.41 Billion DKK | 3.92% |
| 2019 | 2.31 Billion DKK | 37.54% |
| 2018 | 1.68 Billion DKK | 1.08% |
| 2017 | 1.66 Billion DKK | -13.31% |
| 2016 | 1.92 Billion DKK | 23.73% |
| 2015 | 1.55 Billion DKK | 46.01% |
| 2014 | 1.06 Billion DKK | 4.51% |
| 2013 | 1.01 Billion DKK | 2.1% |
| 2012 | 998 Million DKK | -15.92% |
| 2011 | 1.18 Billion DKK | 46.18% |
| 2010 | 812 Million DKK | 12.0% |
| 2009 | 725 Million DKK | 7.25% |
| 2008 | 676 Million DKK | -4.65% |
| 2007 | 709 Million DKK | 2.01% |
| 2006 | 695 Million DKK | -1.7% |
| 2005 | 707 Million DKK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.09 Billion DKK | -8.12% |
| 2024 Q2 | 2.12 Billion DKK | 1.53% |
| 2023 Q3 | 2.22 Billion DKK | -2.02% |
| 2023 Q1 | 2.23 Billion DKK | -3.53% |
| 2023 FY | 2.27 Billion DKK | -1.77% |
| 2023 Q4 | 2.27 Billion DKK | 2.33% |
| 2023 Q2 | 2.27 Billion DKK | 1.56% |
| 2022 Q3 | 2.33 Billion DKK | -3.59% |
| 2022 Q2 | 2.42 Billion DKK | 4.76% |
| 2022 Q1 | 2.31 Billion DKK | -1.66% |
| 2022 FY | 2.32 Billion DKK | -1.28% |
| 2022 Q4 | 2.32 Billion DKK | -0.6% |
| 2021 Q3 | 2.4 Billion DKK | 3.35% |
| 2021 Q4 | 2.35 Billion DKK | -2.25% |
| 2021 FY | 2.35 Billion DKK | -2.49% |
| 2021 Q1 | 2.46 Billion DKK | 2.16% |
| 2021 Q2 | 2.32 Billion DKK | -5.52% |
| 2020 FY | 2.41 Billion DKK | 3.92% |
| 2020 Q1 | 2.36 Billion DKK | 1.77% |
| 2020 Q2 | 2.44 Billion DKK | 3.39% |
| 2020 Q3 | 2.37 Billion DKK | -2.87% |
| 2020 Q4 | 2.41 Billion DKK | 1.69% |
| 2019 Q3 | 1.89 Billion DKK | -2.52% |
| 2019 Q2 | 1.94 Billion DKK | 0.52% |
| 2019 Q4 | 2.31 Billion DKK | 22.18% |
| 2019 Q1 | 1.93 Billion DKK | 14.89% |
| 2019 FY | 2.31 Billion DKK | 37.54% |
| 2018 Q2 | 1.63 Billion DKK | 0.24% |
| 2018 FY | 1.68 Billion DKK | 1.08% |
| 2018 Q3 | 1.57 Billion DKK | -4.09% |
| 2018 Q4 | 1.68 Billion DKK | 7.25% |
| 2018 Q1 | 1.63 Billion DKK | -1.98% |
| 2017 FY | 1.66 Billion DKK | -13.31% |
| 2017 Q3 | 1.74 Billion DKK | -2.95% |
| 2017 Q1 | 2 Billion DKK | 3.95% |
| 2017 Q4 | 1.66 Billion DKK | -4.36% |
| 2017 Q2 | 1.79 Billion DKK | -10.15% |
| 2016 Q2 | 1.66 Billion DKK | 0.0% |
| 2016 FY | 1.92 Billion DKK | 23.73% |
| 2016 Q3 | 1.68 Billion DKK | 1.57% |
| 2016 Q4 | 1.92 Billion DKK | 14.05% |
| 2016 Q1 | 1.66 Billion DKK | 6.82% |
| 2015 Q4 | 1.55 Billion DKK | 5.93% |
| 2015 Q1 | 1.13 Billion DKK | 6.2% |
| 2015 Q2 | 1.42 Billion DKK | 25.91% |
| 2015 Q3 | 1.46 Billion DKK | 3.09% |
| 2015 FY | 1.55 Billion DKK | 46.01% |
| 2014 Q1 | 1.05 Billion DKK | 3.24% |
| 2014 Q2 | 1.02 Billion DKK | -3.04% |
| 2014 Q3 | 1.01 Billion DKK | -0.1% |
| 2014 Q4 | 1.06 Billion DKK | 4.51% |
| 2014 FY | 1.06 Billion DKK | 4.51% |
| 2013 Q2 | 1 Billion DKK | -3.19% |
| 2013 FY | 1.01 Billion DKK | 2.1% |
| 2013 Q4 | 1.01 Billion DKK | 2.0% |
| 2013 Q3 | 999 Million DKK | -0.1% |
| 2013 Q1 | 1.03 Billion DKK | 3.51% |
| 2012 Q4 | 998 Million DKK | 4.61% |
| 2012 FY | 998 Million DKK | -15.92% |
| 2012 Q1 | 1.2 Billion DKK | 1.35% |
| 2012 Q2 | 929 Million DKK | -22.78% |
| 2012 Q3 | 954 Million DKK | 2.69% |
| 2011 Q4 | 1.18 Billion DKK | 39.16% |
| 2011 Q1 | 928 Million DKK | 14.29% |
| 2011 Q2 | 855 Million DKK | -7.87% |
| 2011 Q3 | 853 Million DKK | -0.23% |
| 2011 FY | 1.18 Billion DKK | 46.18% |
| 2010 Q1 | 773 Million DKK | 6.62% |
| 2010 FY | 812 Million DKK | 12.0% |
| 2010 Q4 | 812 Million DKK | 10.48% |
| 2010 Q3 | 735 Million DKK | 6.68% |
| 2010 Q2 | 689 Million DKK | -10.87% |
| 2009 Q4 | 725 Million DKK | 0.0% |
| 2009 FY | 725 Million DKK | 7.25% |
| 2008 FY | 676 Million DKK | -4.65% |
| 2007 FY | 709 Million DKK | 2.01% |
| 2006 FY | 695 Million DKK | -1.7% |
| 2005 FY | 707 Million DKK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bioxytran, Inc. | 3.24 Million USD | -70033.867% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -4175.396% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -540500.805% |
| SQZ Biotechnologies Company | 50.03 Million USD | -4454.448% |
| Intellipharmaceutics International Inc. | 12 Million USD | -18877.802% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -3044.706% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -3761.792% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -59072.919% |
| Marizyme, Inc. | 26.67 Million USD | -8443.352% |
| Genus plc | 485 Million USD | -369.897% |
| Pharming Group N.V. | 244.07 Million USD | -833.737% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -113275.752% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -90468.479% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -59873.684% |
| ContraFect Corporation | 32.53 Million USD | -6905.625% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -59440.48% |
| IMV Inc. | 37.93 Million USD | -5907.994% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -19249.315% |
| ONE Bio Corp. | 27.49 Million USD | -8188.536% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -2843.798% |
| Mesoblast Limited | 188.44 Million USD | -1109.374% |
| MultiCell Technologies, Inc. | 1617.67 USD | -140881538.406% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -2647.935% |
| Genscript Biotech Corporation | 1.32 Billion USD | -71.887% |
| Neon Bloom, Inc. | 1.22 Million USD | -185756.78% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -44186.524% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -23684.124% |
| Biomind Labs Inc. | 1.49 Million USD | -151974.053% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -25104.06% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -12283.571% |
| Skye Bioscience, Inc. | 14.07 Million USD | -16095.018% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -158841.487% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -38906.466% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1603756.575% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -114925.024% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -23975.84% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1133076.873% |
| Accustem Sciences Inc. | 1.07 Million USD | -211067.313% |
| EV Biologics, Inc. | 2.11 Million USD | -107650.622% |
| Q BioMed Inc. | 8.13 Million USD | -27921.85% |
| GB Sciences, Inc. | 5.41 Million USD | -41966.932% |
| Alpha Cognition Inc. | 7.16 Million USD | -31708.4% |
| CSL Limited | 18.62 Billion USD | 87.761% |
| Agentix Corp. | 2.51 Million USD | -90676.741% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -1819.607% |
| Enzolytics Inc. | 365.26 Million USD | -523.924% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 67.39 Million USD | -3281.506% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -271619.691% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -39563.609% |
| argenx SE | 444.95 Million USD | -412.191% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -2941.911% |
| HST Global, Inc. | 593.59 Thousand USD | -383833.099% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -132863.827% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -180888.935% |
| Halberd Corporation | 728.71 Thousand USD | -312640.576% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -9109.559% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -62080.028% |
| Zenith Capital Corp. | 27.56 Thousand USD | -8266431.249% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -19046.271% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -60928.743% |
| AVAX Technologies, Inc. | 3.99 Million USD | -56964.234% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -334636.514% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -83945.049% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -954838.949% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 7.86 Million USD | -28892.211% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -3405000.928% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -4434.06% |
| Kadimastem Ltd | 3.5 Million USD | -64923.865% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | -14229.127% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -490324.985% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -8307412.849% |
| LadRx Corporation | 2.2 Million USD | -103466.053% |
| Cell Source, Inc. | 15.8 Million USD | -14317.924% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -5098790.281% |
| Regen BioPharma, Inc. | 5.45 Million USD | -41658.16% |
| Regen BioPharma, Inc. | 5.45 Million USD | -41658.16% |
| Affymax, Inc. | 8.87 Million USD | -25590.452% |
| Mobile Lads Corp. | 1.31 Million USD | -173406.297% |
| Itoco Inc. | 1.65 Million USD | -137757.945% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -110985.927% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -37575.649% |
| International Stem Cell Corporation | 5.27 Million USD | -43087.417% |
| CytoDyn Inc. | 127.89 Million USD | -1681.944% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -5452183.547% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -145394.986% |
| Qrons Inc. | 1.48 Million USD | -152985.249% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -20533.231% |
| SYBLEU INC | 681.41 Thousand USD | -334352.087% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -281677.56% |
| Rebus Holdings, Inc. | 5.24 Million USD | -43375.773% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -37248.992% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -364068.62% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -49259.721% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -5459.079% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -10135.796% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -112421.706% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -41502.775% |
| Neutra Corp. | 973.52 Thousand USD | -233996.776% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -7754.558% |
| PureTech Health plc | 125.58 Million USD | -1714.736% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -60558.083% |
| IXICO plc | 1.9 Million USD | -119828.937% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -11001.369% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -2105.683% |
| CSL Limited | 18.62 Billion USD | 87.761% |
| Cellectis S.A. | 249.36 Million USD | -813.905% |